Embark Biotech

Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) has announced the purchase of compatriot Embark Biotech, marking a significant step in the discovery and development of drug candidates for obesity and related comorbidities. The acquisition allows Novo Nordisk to incorporate Embark’s lead metabolic program for cardiometabolic diseases, including obesity. The program…